Complex Regional Pain SyndromeNCT03228160
Light Irradiation and Outcome for Neuropathic Pain
A study testing Linearly Polarized Near-Infrared light Irradiation in people with Complex Regional Pain Syndrome, run by Taipei Medical University Shuang Ho Hospital at 1 site in Taiwan.
Trial summary
Background. Sympathetically maintained pain (SMP) can be effectively relieved by light irradiation to the area near stellate ganglion (SGI), which is applied as an alternative to sympathetic blockade. Read more about this study
- Who is it for?
- Ages 20 to 80 years
- Conditions the study is for
- Complex Regional Pain Syndrome
- What is being tested?
- Linearly Polarized Near-Infrared light Irradiation
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 44 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Oct 2016to 31 Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients who age from 20 to 80 years and have a diagnosis of neuropathetic pain will be recruited from the chronic pain center at our hospital.
Who cannot join
- Patients who meted the following criteria are excluded:
- Diagnosis of glioblastoma,
- History of heart disease, serious arrhythmia or pacemaker user,
- Simmond disease or postpartum hypopituitarism,
- Habitual smoking or consumption of stimulant beverages such as tea, coffee, or alcohol, and
- Any other condition that is unsuitable for phototherapy by a doctor's evaluation.
Trial locations and contacts
1 site in 1 country.
Taiwan1 site
Shuang Ho Hospital, Taipei Medical University
New Taipei City, 23561
About this study
Official title: Effects of Linearly Polarized Near-Infrared Irradiation in Patients With Sympathetically Maintained Neuropathic Pain Syndrome
Background. Sympathetically maintained pain (SMP) can be effectively relieved by light irradiation to the area near stellate ganglion (SGI), which is applied as an alternative to sympathetic blockade. The clinical efficiency of SGI on heart rate variability (HRV) and its association with pain outcome need to be further identified.
Objectives. This study is aimed to identify the effects of SGI on pain, HRV indices, quality of life, and function outcomes.
Design. A prospective, double blind, randomized designed study Setting. An outpatient pain medicine clinic Subjects and Methods. A total of 44 patients will be enrolled and randomized to their allocations: the experimental group (EG, n=22) and control group (CG, n=22). All patients in EG will receive 12 sessions (twice a week) of standard SGI, while those in CG go through the same protocol except a shame irradiation is applied. Pain, HRV variables, quality of life, and function outcoms are measured before and after SGI in each session. All measures at the first-half and second-half courses are analyzed.
Read the detailed description
Sympathetically maintained pain (SMP) is defined as an aspect of pain which is maintained or mediated by sympathetic efferent activity including the action of circulating catecholamine and is often linked to the complex regional pain syndrome (CRPS). SMP has been categorized as a subset of neuropathic pain mediated by the underlying mechanism of peripheral sensitization referring to noradrenergic sensitization of peripheral afferent nociceptive fibers and a pathologically sympathetic-sensory coupling interaction between the efferent sympathetic and the afferent system. Besides, SMP is associated with vasomotor and sudomotor dysfunction through either peripheral integerized by an adrenoreceptor stimulated or central organized by sensitization. Therefore, modulation of sympathetic activity either by means of pharmacological analgesics or local sympathetic ganglion blockade may influence the pain course in patients with chronic pain and hyperalgesia that were suspected to be sympathetically maintained.
The pain associated with sympathetic activity can be relieved by blockage of efferent sympathetic nerves to the affected area. Stellate ganglion block (SGB), a local anesthetic blockade of sympathetic ganglia, has been advocated as an early intervention to achieve sympatholysis and its strong evidence had been identified. However, a success of SGB depends on the skilled invasive technique in application and several potential complications may be elucidated. Alternatively, the light irradiation near the stellate ganglion region (SGI) using either low-reactive level laser or linear-polarized near-infrared light irradiation had been used as a noninvasive method for local anesthetic sympathetic blockade. Furthermore, SGI can be safely and conveniently performed in clinical practice even when an anesthetic physician is not available, had been well tolerated by patients, and no thermal injury or side effects were reported by literatures.
SGI had been identified to offer similar effects of SGB for patients with neuropathic pain, including improving blood flow by dilating vessels and reducing pain by directly blocking afferent nociceptive signal traveling via sympathetic pathways. The irradiation effect on heart rate variability (HRV), which is an objectively non-invasive marker of the autonomic nervous system, had not yet been well established. If the pathogenesis of SMP is closely referred to some abnormality in the function of autonomic nerve system (ANS), it is more necessary to measure autonomic activity for validation rather than pain status, local temperature or peripheral blood flow. Whether the relieved pain level after SGI is associated to HRV changes remains unclear. Identifying the relationship between HRV and pain status following SGI allows the clinicians to set a prompt protocol of phototherapy using SGI, and to accurately follow the outcome of autonomic dysfunction in patients with SMP.
The purpose of this study was to demonstrate the sympatholytic and clinical effects of linear polarized near-infrared irradiation applied on stellate ganglion in patients with SMP.
An experimental design with two groups will be used and a double blind, prospective randomized control trial will be conducted at the chronic pain medicine center in the physical medicine and rehabilitation department. Potential patients will be recruited. The enrolled patients will be randomly assigned to the experimental group or the control group (CG) using a table of random numbers. Patients in the experimental group will receive a 6-week standard SGI treatment protocol (12 irradiation sessions), while those in the control group being undergo a sham irradiation during the same period. Both the investigators and the patients will be blinded to the group assignments. All outcome measures will be collected by a trained research assistant at the baseline admission prior to SGI therapy, before and after SGI at each irradiation session, and at the follow up admission immediately after the end of 6-week treatment period.
- Conditions
- Complex Regional Pain Syndrome
- Being tested
- Linearly Polarized Near-Infrared light Irradiation
- Keywords
- Sympathetically Maintained Pain, Linear-Polarized Near-Infrared Irradiation, Stellate Ganglion, Heart Rate Variability, Autonomic Dysfunction Outcome
- Medical subject headings
- Complex Regional Pain Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Linearly Polarized Near-Infrared light IrradiationOther
Also called Phototherapy
The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
| Study group | Role | What they receive |
|---|---|---|
| SGI irradiation | Experimental | Experimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion. Receives: Other: Linearly Polarized Near-Infrared light Irradiation |
| Shame irradiation | Sham comparator | Control group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion. Receives: Other: Linearly Polarized Near-Infrared light Irradiation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual analogue scale (VAS: 0-100mm)
A visual analogue scale (VAS: 0-100mm) representing pain intensity, where 0 represented no pain and 100 indicated unbearable pain. Participants are instructed to indicate a point on the scale corresponding to the pain intensity. The distance from the left end to the selected point is measured to calculate the pain score in millimeters.
Measured: Baseline
Visual analogue scale (VAS: 0-100mm)
A visual analogue scale (VAS: 0-100mm) representing pain intensity, where 0 represented no pain and 100 indicated unbearable pain. Participants are instructed to indicate a point on the scale corresponding to the pain intensity. The distance from the left end to the selected point is measured to calculate the pain score in millimeters.
Measured: Follow up at 3 months (end of intervention)
Secondary outcomes (6)
Short Form (36) Health Surve (SF-36)
Assessment of quality of life
Measured: Baseline, follow up at 3 months after end of intervention
Short Form (36) Health Surve (SF-36)
Assessment of quality of life
Measured: Follow up at 3 months after end of intervention
Disability of the Arm, Shoulder and Hand (DASH)
Function evaluation of upper quarter
Measured: Baseline, follow up at 3 months after end of intervention
Disability of the Arm, Shoulder and Hand (DASH)
Function evaluation of upper quarter
Measured: Follow up at 3 months after end of intervention
Heart rate variability (HRV) analysis
HRV was measured using an ANSWatch wrist monitor (Taiwan Scientific Co., Taipei, Taiwan).
Measured: Baseline, follow up at 3 months after end of intervention
Heart rate variability (HRV) analysis
HRV was measured using an ANSWatch wrist monitor (Taiwan Scientific Co., Taipei, Taiwan).
Measured: Follow up at 3 months after end of intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2017
- Study start1 Oct 2016
- Primary completion1 Dec 2022 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Complex Regional Pain SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 44 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Taipei Medical University Shuang Ho Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Chun-De Liao, PT, Taipei Medical University Shuang Ho Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03228160
- Sponsor's protocol ID
- N201511030
- Status last verified
- May 2022
- First submitted
- 29 Jan 2016
- Last updated
- 4 May 2022
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Linearly Polarized Near-Infrared Irradiation in Patients With Sympathetically Maintained Neuropathic Pain Syndrome
- ClinicalTrials.gov ID
- NCT03228160
- Acronym / sponsor ID
- N201511030
- Conditions
- Complex Regional Pain Syndrome
- Keywords
- Sympathetically Maintained Pain, Linear-Polarized Near-Infrared Irradiation, Stellate Ganglion, Heart Rate Variability, Autonomic Dysfunction Outcome
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 44 participants (estimated)
- Lead sponsor
- Taipei Medical University Shuang Ho HospitalUniversity, hospital or other
- Study start
- 1 Oct 2016 (actual)
- Primary completion
- 1 Dec 2022 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 24 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background. Sympathetically maintained pain (SMP) can be effectively relieved by light irradiation to the area near stellate ganglion (SGI), which is applied as an alternative to sympathetic blockade. The clinical efficiency of SGI on heart rate variability (HRV) and its association with pain outcome need to be further identified.
Objectives. This study is aimed to identify the effects of SGI on pain, HRV indices, quality of life, and function outcomes.
Design. A prospective, double blind, randomized designed study Setting. An outpatient pain medicine clinic Subjects and Methods. A total of 44 patients will be enrolled and randomized to their allocations: the experimental group (EG, n=22) and control group (CG, n=22). All patients in EG will receive 12 sessions (twice a week) of standard SGI, while those in CG go through the same protocol except a shame irradiation is applied. Pain, HRV variables, quality of life, and function outcoms are measured before and after SGI in each session. All measures at the first-half and second-half courses are analyzed.
Detailed description
Sympathetically maintained pain (SMP) is defined as an aspect of pain which is maintained or mediated by sympathetic efferent activity including the action of circulating catecholamine and is often linked to the complex regional pain syndrome (CRPS). SMP has been categorized as a subset of neuropathic pain mediated by the underlying mechanism of peripheral sensitization referring to noradrenergic sensitization of peripheral afferent nociceptive fibers and a pathologically sympathetic-sensory coupling interaction between the efferent sympathetic and the afferent system. Besides, SMP is associated with vasomotor and sudomotor dysfunction through either peripheral integerized by an adrenoreceptor stimulated or central organized by sensitization. Therefore, modulation of sympathetic activity either by means of pharmacological analgesics or local sympathetic ganglion blockade may influence the pain course in patients with chronic pain and hyperalgesia that were suspected to be sympathetically maintained.
The pain associated with sympathetic activity can be relieved by blockage of efferent sympathetic nerves to the affected area. Stellate ganglion block (SGB), a local anesthetic blockade of sympathetic ganglia, has been advocated as an early intervention to achieve sympatholysis and its strong evidence had been identified. However, a success of SGB depends on the skilled invasive technique in application and several potential complications may be elucidated. Alternatively, the light irradiation near the stellate ganglion region (SGI) using either low-reactive level laser or linear-polarized near-infrared light irradiation had been used as a noninvasive method for local anesthetic sympathetic blockade. Furthermore, SGI can be safely and conveniently performed in clinical practice even when an anesthetic physician is not available, had been well tolerated by patients, and no thermal injury or side effects were reported by literatures.
SGI had been identified to offer similar effects of SGB for patients with neuropathic pain, including improving blood flow by dilating vessels and reducing pain by directly blocking afferent nociceptive signal traveling via sympathetic pathways. The irradiation effect on heart rate variability (HRV), which is an objectively non-invasive marker of the autonomic nervous system, had not yet been well established. If the pathogenesis of SMP is closely referred to some abnormality in the function of autonomic nerve system (ANS), it is more necessary to measure autonomic activity for validation rather than pain status, local temperature or peripheral blood flow. Whether the relieved pain level after SGI is associated to HRV changes remains unclear. Identifying the relationship between HRV and pain status following SGI allows the clinicians to set a prompt protocol of phototherapy using SGI, and to accurately follow the outcome of autonomic dysfunction in patients with SMP.
The purpose of this study was to demonstrate the sympatholytic and clinical effects of linear polarized near-infrared irradiation applied on stellate ganglion in patients with SMP.
An experimental design with two groups will be used and a double blind, prospective randomized control trial will be conducted at the chronic pain medicine center in the physical medicine and rehabilitation department. Potential patients will be recruited. The enrolled patients will be randomly assigned to the experimental group or the control group (CG) using a table of random numbers. Patients in the experimental group will receive a 6-week standard SGI treatment protocol (12 irradiation sessions), while those in the control group being undergo a sham irradiation during the same period. Both the investigators and the patients will be blinded to the group assignments. All outcome measures will be collected by a trained research assistant at the baseline admission prior to SGI therapy, before and after SGI at each irradiation session, and at the follow up admission immediately after the end of 6-week treatment period.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SGI irradiation | Experimental | Other: Linearly Polarized Near-Infrared light IrradiationExperimental group with active Linearly Polarized Near-Infrared light irradiation to stellate ganglion. |
| Shame irradiation | Sham comparator | Other: Linearly Polarized Near-Infrared light IrradiationControl group with shame Linearly Polarized Near-Infrared light irradiation to stellate ganglion. |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients who age from 20 to 80 years and have a diagnosis of neuropathetic pain will be recruited from the chronic pain center at our hospital.
Key exclusion criteria (6 listed)
- Patients who meted the following criteria are excluded:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Linearly Polarized Near-Infrared light IrradiationAlso: PhototherapyThe SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m-⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive. | Other | SGI irradiation, Shame irradiation |
Primary outcome
Visual analogue scale (VAS: 0-100mm)
Time frame: Baseline
A visual analogue scale (VAS: 0-100mm) representing pain intensity, where 0 represented no pain and 100 indicated unbearable pain. Participants are instructed to indicate a point on the scale corresponding to the pain intensity. The distance from the left end to the selected point is measured to calculate the pain score in millimeters.
Visual analogue scale (VAS: 0-100mm)
Time frame: Follow up at 3 months (end of intervention)
A visual analogue scale (VAS: 0-100mm) representing pain intensity, where 0 represented no pain and 100 indicated unbearable pain. Participants are instructed to indicate a point on the scale corresponding to the pain intensity. The distance from the left end to the selected point is measured to calculate the pain score in millimeters.
6 secondary outcomes
Short Form (36) Health Surve (SF-36)
Time frame: Baseline, follow up at 3 months after end of intervention
Short Form (36) Health Surve (SF-36)
Time frame: Follow up at 3 months after end of intervention
Disability of the Arm, Shoulder and Hand (DASH)
Time frame: Baseline, follow up at 3 months after end of intervention
Disability of the Arm, Shoulder and Hand (DASH)
Time frame: Follow up at 3 months after end of intervention
Heart rate variability (HRV) analysis
Time frame: Baseline, follow up at 3 months after end of intervention
Heart rate variability (HRV) analysis
Time frame: Follow up at 3 months after end of intervention
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 May 2022.
- Individual participant dataSharing planned: No
Related trials for Complex Regional Pain Syndrome
Enrolling by invitationPhase 4
Low Dose Naltrexone Therapy for Complex Regional Pain Syndrome
Complex Regional Pain Syndrome, Chronic Pain
RecruitingPhase 3
Evaluation of IV AMBTX-01 (Neridronate) for Treatment of CRPS Type 1 (CRPS-RISE)
Complex Regional Pain Syndrome Type I
Recruiting
The Effectiveness of Conservative Treatment in Patients With Complex Regional Pain Syndrome.
CRPS (Complex Regional Pain Syndromes)
RecruitingPhase 3
Phase 3, Open-Label Extension Study of AMBTX-01 (Neridronate) for Complex Regional Pain Syndrome Type 1
Complex Regional Pain Syndrome Type I
Active, not recruiting
Transcranial Magnetic Stimulation for Chronic Neuropathic Pain
Chronic Neuropathic Pain, Post-Stroke Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Linearly Polarized Near-Infrared light Irradiation in people with Complex Regional Pain Syndrome, run by Taipei Medical University Shuang Ho Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 4 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual analogue scale (VAS: 0-100mm) (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2022.